Top 10 biotech M&A deals drive record 2025 activity

2025 saw a resurgence of major deals in the biotech sector, building on a $14.6 billion deal at the start of the year and outperforming dealmaking in 2024. Ailsa Craig notes that biotech companies were responsible for over 70% of new drug approvals last year, making acquisitions the most effective way for pharmaceutical companies to innovate.